Technology Appraisal Committee Meeting (Committee A)  
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: 16 October 2018, 10am- 5pm

Present:
1. Chair Jane Adam Present for all notes
2. Professor Iain Squire Present for all notes
3. Dr Steve Edwards Present for Notes 11 to 27
4. Dr Rita Faria Present for all notes
5. Ms Pamela Rees Present for all notes
6. Dr Brian Shine Present for all notes
7. Dr John Watkins Present for all notes
8. Dr Min Ven Teo Present for all notes
9. Dr Justin Daniels Present for all notes
10. Sumithra Maheswaran Present for all notes
11. Dr Mohit Sharma Present for all notes
12. Mrs Sarah Parry Present for all notes
13. Professor Olivia Wu Present for all notes
14. Dr Rachel Hobson Present for all notes
15. Mr Stephen Sharp Present for all notes
16. Dr Alice Turner Present for all notes
17. Dr Roger Whittaker Present for all notes
18. Dr Jeremy Braybrooke Present for all notes

In attendance:

Helen Knight  Programme Director, National Institute for Health and Care Excellence Present for all notes

Janet Robertson  Associate Director, National Institute for Health and Care Excellence Present for all notes

Thomas Feist  Project Manager, National Institute for Health and Care Excellence Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcia Miller</td>
<td>Technology Appraisal Administrator, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>Boglarka Mikudina</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>1 to 10</td>
</tr>
<tr>
<td>Zoe Charles</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>1 to 10</td>
</tr>
<tr>
<td>Juliet Kenny</td>
<td>Technical Analyst National Institute of Health and Care Excellence</td>
<td>19 to 27</td>
</tr>
</tbody>
</table>

**Non-public attendees:**

**ERG Team – BMJ-TAG**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Steve Edwards</td>
<td>Director of Health Technology Assessment Health Economist</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Tracey Jhita</td>
<td>Health Economist</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Charlotta Karner</td>
<td>Health Economist</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Dr Peter Cain Vicky Wakefield</td>
<td>Senior Health Economist</td>
<td>1 to 8</td>
</tr>
</tbody>
</table>

**ERG Team – Warwick Evidence**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Gallacher</td>
<td>Health Economist</td>
<td>11 to 16</td>
</tr>
<tr>
<td>Dr Chidoze Nduka</td>
<td>Health Economist</td>
<td>11 to 16</td>
</tr>
</tbody>
</table>

**Experts**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alison Dejal</td>
<td>Patient expert, nominated by the Eve Appeal</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Diane Cannon</td>
<td>Patient expert nominated by Melanoma UK</td>
<td>11 to 16</td>
</tr>
<tr>
<td>Dr Sadaf Ghaem-Maghami</td>
<td>Consultant Gynaecological Oncologist, RCOG</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Name</td>
<td>Position and Affiliations</td>
<td>Present for notes</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Professor Charlie Gourley</td>
<td>Chair of Medical Oncology and Honorary Consultant in Medical Oncology. Director, Nicola Murray Centre for Ovarian Cancer Research</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Dr James Larkin</td>
<td>Consultant Medical Oncologist, Royal Marsden, nominated by BMS</td>
<td>11 to 16</td>
</tr>
<tr>
<td>Melanie Sturtevant</td>
<td>Patient expert nominated by Breast Cancer Now</td>
<td>19 to 23</td>
</tr>
<tr>
<td>Dr Sharon Tate</td>
<td>Head of Primary Care Development nominated by Target Ovarian Cancer</td>
<td>1 to 8</td>
</tr>
<tr>
<td>Dr Andrew Wardley</td>
<td>Consultant &amp; MAHSC Honorary Chair in Breast Medical Oncology nominated by ROCHE</td>
<td>1 to 8 and 19 to 23</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [ID1296]

2. Apologies were received from: Dr Graham Ash, Mr Adrian Griffin, Professor John McMurray, Dr Minal Bakhai and Dr Paul Robinson

Appraisal of Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [ID1296]

Part 1 – Open session

3. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.

4. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

   4.1. Dr Rita Faria declared a non-personal specific financial interest as she carried out some consultancy work back in 2014 in relation to the drug Olaparib.  
   5.1.1 It was agreed that this declaration would not prevent participation in the meeting.

   4.2. Dr Alice Turner declared a non-personal specific financial interest as she received a research from the company for work in an unrelated field.  
   5.2.1 It was agreed that this declaration would not prevent participation in the meeting.

5. The Chair introduced the lead team Dr Jeremy Braybrooke, Ms Pamela Rees and Mr Stephen Sharp, who gave presentations on the clinical effectiveness and cost effectiveness of Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

7. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

8. The Chair then thanked the ERG representatives, experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

9. Discussion on confidential information continued. This information was supplied by the company.

9.1. The committee decision was based on consensus.

10. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316]

Part 1 – Open session

11. The Chair welcomed the invited clinical and patient experts, evidence review group (ERG) representatives and representatives from AstraZeneca.

12. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests:

12.1. No declaration of interests were made for the topic.

13. The Chair introduced the lead team, Professor Olivia Wu. Dr Jane Adam and Professor Olivia Wu gave a presentation on the clinical effectiveness and cost effectiveness of Nivolumab for adjuvant treatment of resected stage III and IV melanoma.

14. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

15. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
16. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

17. The committee decision was based on consensus.

18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of Pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192]**

**Part 2 – closed session**

19. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.

20. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

24. Discussion on confidential information continued. This information was supplied by the company.

25. The committee decision was based on consensus.

26. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

27. Thursday 15 November 2018, 10am at National Institute for Health and Care Excellence, 10 Spring Gardens, SW1A 2BU.